Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers.
Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S, Sukapirom K, Sapsutthipas S, Sirijatuphat R, Wittawatmongkol O, Senawong S, Mahasirimongkol S, Trisiriwanich S, Chokephaibulkit K. Angkasekwinai N, et al. Among authors: mahasirimongkol s. Vaccine X. 2022 Mar 5;10:100153. doi: 10.1016/j.jvacx.2022.100153. eCollection 2022 Apr. Vaccine X. 2022. PMID: 35282410 Free PMC article.
Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
Intapiboon P, Seepathomnarong P, Ongarj J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Sangsupawanich P, Chusri S, Pinpathomrat N. Intapiboon P, et al. Among authors: mahasirimongkol s. Vaccines (Basel). 2021 Nov 23;9(12):1375. doi: 10.3390/vaccines9121375. Vaccines (Basel). 2021. PMID: 34960122 Free PMC article.
The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
Mahasirimongkol S, Khunphon A, Kwangsukstid O, Sapsutthipas S, Wichaidit M, Rojanawiwat A, Wichuckchinda N, Puangtubtim W, Pimpapai W, Soonthorncharttrawat S, Wanitchang A, Jongkaewwattana A, Srisutthisamphan K, Phainupong D, Thawong N, Piboonsiri P, Sawaengdee W, Somsaard T, Ritthitham K, Chumpol S, Pinyosukhee N, Wichajarn R, Dhepakson P, Iamsirithaworn S, Phumiamorn S. Mahasirimongkol S, et al. Vaccines (Basel). 2022 Mar 30;10(4):536. doi: 10.3390/vaccines10040536. Vaccines (Basel). 2022. PMID: 35455285 Free PMC article.
Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.
Pinpathomrat N, Intapiboon P, Seepathomnarong P, Ongarj J, Sophonmanee R, Hengprakop J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Kongkamol C, Ingviya T, Sangsupawanich P, Chusri S. Pinpathomrat N, et al. Among authors: mahasirimongkol s. NPJ Vaccines. 2022 May 13;7(1):52. doi: 10.1038/s41541-022-00475-z. NPJ Vaccines. 2022. PMID: 35562372 Free PMC article.
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study.
Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, Rattanasompattikul M, Mahasirimongkol S, Wichukchinda N, Chokephaibulkit K. Sirijatuphat R, et al. Among authors: mahasirimongkol s. Emerg Microbes Infect. 2022 Dec;11(1):2197-2206. doi: 10.1080/22221751.2022.2117092. Emerg Microbes Infect. 2022. PMID: 35997325 Free PMC article. Clinical Trial.
Author Correction: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population.
Pinpathomrat N, Intapiboon P, Seepathomnarong P, Ongarj J, Sophonmanee R, Hengprakop J, Surasombatpattana S, Uppanisakorn S, Mahasirimongkol S, Sawaengdee W, Phumiamorn S, Sapsutthipas S, Kongkamol C, Ingviya T, Sangsupawanich P, Chusri S. Pinpathomrat N, et al. Among authors: mahasirimongkol s. NPJ Vaccines. 2022 Sep 6;7(1):107. doi: 10.1038/s41541-022-00529-2. NPJ Vaccines. 2022. PMID: 36068243 Free PMC article. No abstract available.
A Multiplexed Cas13-Based Assay with Point-of-Care Attributes for Simultaneous COVID-19 Diagnosis and Variant Surveillance.
Patchsung M, Homchan A, Aphicho K, Suraritdechachai S, Wanitchanon T, Pattama A, Sappakhaw K, Meesawat P, Wongsatit T, Athipanyasilp A, Jantarug K, Athipanyasilp N, Buahom J, Visanpattanasin S, Niljianskul N, Chaiyen P, Tinikul R, Wichukchinda N, Mahasirimongkol S, Sirijatuphat R, Angkasekwinai N, Crone MA, Freemont PS, Joung J, Ladha A, Abudayyeh O, Gootenberg J, Zhang F, Chewapreecha C, Chanarat S, Horthongkham N, Pakotiprapha D, Uttamapinant C. Patchsung M, et al. Among authors: mahasirimongkol s. CRISPR J. 2023 Apr;6(2):99-115. doi: 10.1089/crispr.2022.0048. Epub 2022 Nov 11. CRISPR J. 2023. PMID: 36367987 Free PMC article.
SARS-CoV-2 Seroprevalence in Unvaccinated Adults in Thailand in November 2021.
Mahasirimongkol S, Uppapong B, Puangtubtim W, Dhepakson P, Panyajai P, Thawong N, Pinyosukhee N, Rojanawiwat A, Wichukchinda N, Soonthorncharttrawat S, Larpardisorn K, Amonyingcharoen S, Juntaped K, Chaiyakum T, Tongkamsen C, Srilaket J, Chipatoom J, Wichajarn R, Chatchawankanpanich N, Pattarapreeyakul L, Chaiya P, Mongkolsiri K, Tuntigumthon S, Sophondilok K, Saengtong N, Jongpitisub K, Sirilak S. Mahasirimongkol S, et al. Vaccines (Basel). 2022 Dec 16;10(12):2169. doi: 10.3390/vaccines10122169. Vaccines (Basel). 2022. PMID: 36560579 Free PMC article.
Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case-Control Study.
Nittayasoot N, Suphanchaimat R, Thammawijaya P, Jiraphongsa C, Siraprapasiri T, Ploddi K, Pittayawonganon C, Mahasirimongkol S, Tharmaphornpilas P. Nittayasoot N, et al. Among authors: mahasirimongkol s. Vaccines (Basel). 2022 Dec 12;10(12):2123. doi: 10.3390/vaccines10122123. Vaccines (Basel). 2022. PMID: 36560533 Free PMC article.
130 results